# Dual peptide presentation from bioengineered carriers to potentiate stromal cell function and tissue repair

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2021 · $468,895

## Abstract

PROJECT SUMMARY
Of the greater than 6 million fractures occurring yearly in the US, 5-20% will result in nonunion or delayed
union. Cell based therapies represent an exciting alternative to traditional bone grafting or implants, but cell
transplantation requires a tailorable substrate to provide necessary cues to implanted cells. Mesenchymal
stem/stromal cells (MSCs) are an attractive cell source for use in tissue engineering because of their robust
secretion of proangiogenic and anti-inflammatory trophic factors. Upon appropriate stimulation, MSCs can
directly contribute to bone formation by differentiating to bone-forming osteoblasts, yet osteogenically induced
MSCs suffer from reduced secretion of proangiogenic factors. We demonstrated that the presentation of a
proangiogenic peptide, Gly-His-Lys (GHK), to MSCs entrapped in alginate hydrogels resulted in up to a 4-fold
increase in their proangiogenic potential. We previously incorporated peptide ligands such as Arg-Gly-Asp
(RGD) to facilitate cell adhesion to ionically-crosslinked alginate and photocrosslinkable alginate gels (PAHs)
with more controlled degradation profiles. RGD stimulates osteogenic differentiation of MSCs but may impair
secretion of endogenous proangiogenic cues. Thus, there is a pressing need for biomaterials that can
simultaneously enhance the proangiogenic and osteogenic potential of transplanted MSCs to maximize their
efficacy in cell based therapies. Our central hypothesis is MSCs can be simultaneously stimulated to undergo
osteogenic differentiation while secreting potent proangiogenic cues, translating to enhanced therapeutic
potential by increasing local vascularization and bone formation. Aim 1. Determine the role of dual peptide
signaling on MSC osteogenic differentiation and proangiogenic potential when entrapped in PAHs. We
will synthesize PAHs with varying densities of RGD and GHK. Changes in the biophysical properties of the gel,
as well as the osteogenic and proangiogenic response of entrapped human MSCs will be determined. Aim 2.
Define the necessary biophysical properties of peptide-presenting PAHs to instruct MSC osteogenic
and proangiogenic potential. We will examine the role of each peptide on osteogenic differentiation and
proangiogenic potential, while measuring the contributions of cell adhesion and substrate bulk stiffness to MSC
response. Aim 3. Demonstrate the therapeutic potential of MSCs deployed in dual peptide-modified
alginate to promote vascularization and bone repair in rodent critical-sized calvarial bone defects. We
will characterize the capacity of MSCs implanted in peptide-presenting PAHs to promote bone repair in an
orthotopic defect. The role of implanted cells, quantity, and quality of bone formation will be assessed using
noninvasive imaging modalities and histological analysis. The proposed research is innovative because it
exploits the activity of two distinct peptides with a biodegradable hydrogel to potentiate the reparative poten...

## Key facts

- **NIH application ID:** 10130378
- **Project number:** 5R01DE025899-05
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** J. Kent Leach
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $468,895
- **Award type:** 5
- **Project period:** 2017-04-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10130378

## Citation

> US National Institutes of Health, RePORTER application 10130378, Dual peptide presentation from bioengineered carriers to potentiate stromal cell function and tissue repair (5R01DE025899-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10130378. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
